SAN FRANCISCO, Jan. 3, 2025 /PRNewswire/ -- Shares of BioAge (NASDAQ: BIOA) have plummeted since the company's December 6 announcement of the discontinuation of a Phase 2 trial for its weight-loss drug azelaprag due to safety concerns. The abrupt halt comes just a little over two months after the company raised $198 million in a highly anticipated initial public offering in late September.Hagens Berman has opened an investigation into whether BioAge's IPO documents may have contained misstatements or omissi ...

NEW YORK, Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether BioAge and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On or around September 26 ...

BOSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BioAge Labs, Inc. (NASDAQ:BIOA) for potential securities law violations. Investors who have lost money in their BioAge Labs, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bioa. What is this all about? Shares of BioAge Labs, Inc. were down 73% on December 9, after the company discontinued its STRIDES Phase 2 trial for azelaprag, c ...

BOSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BioAge Labs, Inc. (Nasdaq: BIOA) for potential securities law violations. Investors who have lost money in their BioAge Labs, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bioa. What is this all about? Shares of BioAge Labs, Inc. were down 73% on December 9, after the company discontinued its STRIDES Phase 2 trial for azelaprag, ...

STOCKHOLM, Dec. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic's BrainTransporter™ technology. As part of the agreement, BioArctic will receive a USD 100 million upfront payment and up to USD 1.25 billion in milestone payments. ...

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company devel ...

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ:BIOA). The investigation concerns whether BioAge and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for its lead product candidate, azelapr ...

SAN FRANCISCO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- On December 9, 2024, just months after conducting an initial public offering in September 2024, BioAge Labs, Inc. (NASDAQ: BIOA) made the startling announcement that it was discontinuing a Phase 2 study for its lead product, azelaprag, intended to treat metabolic diseases such as obesity. Hagens Berman has opened an investigation and urges investors in BioAge who purchased shares in the company’s IPO or on the open market and suffered substantial losses to su ...

NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Why is BioAge being Investigated? BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therap ...

ATLANTA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) complied with federal securities laws. On December 6, 2024, BioAge announced the discontinuation of the Strides Phase 2 study of its investigational drug candidate azelaprag due to safety concerns “after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag.”  Following this news, the price of the Company ...